Search Results - "Balow, J"

Clinical presentation and monitoring of lupus nephritis by Balow, J E

“…The diversity of clinical presentations of lupus nephritis parallel the diversity of pathologic lesions seen in the kidneys of patients with SLE. Renal…”
Get full text

Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies by Malek, R., Chong, A. Y., Lupsa, B. C., Lungu, A. O., Cochran, E. K., Soos, M. A., Semple, R. K., Balow, J. E., Gorden, P.

“…Background: Type B insulin resistance belongs to a class of diseases caused by an autoantibody to a cell surface receptor. Blockade of insulin action results…”
Get full text

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis by ILLEI, Gabor G, AUSTIN, Howard A, KLIPPEL, John H, BALOW, James E, BOUMPAS, Dimitrios T, CRANE, Marianna, COLLINS, Lee, GOURLEY, Mark F, YARBORO, Cheryl H, VAUGHAN, Ellen M, KUROIWA, Takashi, DANNING, Carol L, STEINBERG, Alfred D

“…Controlled trials in lupus nephritis have demonstrated that cyclophosphamide therapy is superior to corticosteroid therapy alone. The long-term effectiveness…”
Get full text

Nephrotic syndrome: an under‐recognised immune‐mediated complication of non‐myeloablative allogeneic haematopoietic cell transplantation by Srinivasan, R., Balow, J. E., Sabnis, S., Lundqvist, A., Igarashi, T., Takahashi, Y., Austin, H., Tisdale, J., Barrett, J., Geller, N., Childs, R.

“…Summary Nephrotic syndrome (NS) is an extremely rare complication of myeloablative allogeneic haematopoietic cell transplantation (HCT) that usually occurs in…”
Get full text

Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor by Paliogianni, F, Ahuja, SS, Balow, JP, Balow, JE, Boumpas, DT

“…Interaction of IL-2 with its high affinity membrane receptor complex (IL-2R) present on activated T lymphocytes induces cell proliferation and mediates…”
Get full text

Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis : A randomized, controlled trial by GOURLEY, M. F, AUSTIN, H. A, SCOTT, D, YARBORO, C. H, VAUGHAN, E. M, MUIR, J, BOUMPAS, D. T, KLIPPEL, J. H, BALOW, J. E, STEINBERG, A. D

“…Uncertainty exists about the efficacy and toxicity of bolus therapy with methylprednisolone or of the combination of methylprednisolone and cyclophosphamide in…”
Get full text

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis by Boumpas, D T, Austin, 3rd, H A, Vaughn, E M, Klippel, J H, Steinberg, A D, Yarboro, C H, Balow, J E

“…Pulse cyclophosphamide is more effective than prednisone alone in preventing renal failure in lupus nephritis. We undertook a randomised, controlled trial to…”
Get more information

Glucocorticoid therapy for immune-mediated diseases : basic and clinical correlates by BOUMPAS, D. T, CHROUSOS, G. P, WILDECR, R. L, CUPPS, T. R, BALOW, J. E

“…Glucocorticoids are pleiotropic hormones that at pharmacologic doses prevent or suppress inflammation and other immunologically mediated processes. At the…”
Get full text

Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial by Schiffmann, Raphael, Kopp, Jeffrey B, Austin III, Howard A, Sabnis, Sharda, Moore, David F, Weibel, Thais, Balow, James E, Brady, Roscoe O

“…CONTEXT Fabry disease is a metabolic disorder without a specific treatment, caused by a deficiency of the lysosomal enzyme α-galactosidase A (α-gal A). Most…”
Get full text

Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis by Illei, G. G., Yarboro, C. H., Kuroiwa, T., Schlimgen, R., Austin, H. A., Tisdale, J. F., Chitkara, P., Fleisher, T., Klippel, J. H., Balow, J. E., Boumpas, D. T.

“…Objectives. To determine the safety and efficacy of a short course of fludarabine combined with cyclophoshamide in lupus nephritis. Methods. A phase I/II open…”
Get full text

High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients by Austin, 3rd, H A, Boumpas, D T, Vaughan, E M, Balow, J E

“…The pleomorphic nature of lupus nephritis has confounded efforts to refine estimates of prognosis. Consideration of interactions among prognostic factors may…”
Get more information

Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy by BOUMPAS, D. T, AUSTIN, H. A, VAUGHAN, E. M, YARBORO, C. H, KLIPPEL, J. H, BALOW, J. E

“…To determine the risk for secondary amenorrhea after pulse cyclophosphamide therapy in premenopausal women with systemic lupus erythematosus. Controlled,…”
Get full text

Mapping of a Gene Causing Familial Mediterranean Fever to the Short Arm of Chromosome 16 by Pras, Elon, Pras, Mordechai, Aksentijevich, Ivona, Gruberg, Luis, Balow, James E, Prosen, Leandrea, Dean, Michael, Steinberg, Alfred D, Kastner, Daniel L

“…Familial Mediterranean fever is a disorder characterized by intermittent attacks of fever with abdominal pain, pleurisy, or arthritis; its symptoms are not…”
Get full text

Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels by Anastassiou, ED, Paliogianni, F, Balow, JP, Yamada, H, Boumpas, DT

“…cAMP is an intracellular second messenger that conveys inhibitory signals for T cell activation and clonal proliferation. cAMP also inhibits the production of…”
Get full text

Outcome criteria for lupus nephritis trials: a critical overview by Boumpas, D T, Balow, J E

“…Lupus nephritis is an important cause of morbidity and mortality in patients with systemic lupus erythematosus. Traditional outcome criteria such as doubling…”
Get more information

Recombinant human Dnase I (rhDNase) in patients with lupus nephritis by Davis, J C, Manzi, S, Yarboro, C, Rairie, J, Mcinnes, I, Averthelyi, D, Sinicropi, D, Hale, V G, Balow, J, Austin, H, Boumpas, D T, Klippel, J H

“…Systemic lupus erythematosus (SLE) is characterized by the production of pathogenic autoantibodies to nucleoprotein antigens, including double-stranded DNA…”
Get full text

Renal biopsy in lupus nephritis by Grande, J P, Balow, J E

“…Renal biopsy can be extremely valuable in the management of patients with lupus nephritis. It is remarkably common to find pathological evidence of substantial…”
Get more information

Analysis of CARD15 NOD2 haplotypes fails to identify common variants associated with rheumatoid arthritis susceptibility by Addo, A., Le, J., Li, W., Aksentijevich, I., Balow Jr, J., Lee, A., Gregersen, P. K., Kastner, D. L., Remmers, E. F.

“…Objectives: The CARD15 NOD2 gene product plays an important role in host response to bacterial lipopolysaccharides and bacterial muramyl dipeptide via…”
Get full text

Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2 : Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity by LANGFORD, C. A, KLIPPEL, J. H, BALOW, J. E, JAMES, S. P, SNELLER, M. C

“…When cytotoxic agents were introduced, their ability to disrupt nucleic acid and protein synthesis led to their effective use for the treatment of neoplastic…”
Get full text

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs by Austin, 3rd, H A, Klippel, J H, Balow, J E, le Riche, N G, Steinberg, A D, Plotz, P H, Decker, J L

“…We evaluated renal function in 107 patients with active lupus nephritis who participated in long-term randomized therapeutic trials (median follow-up, seven…”
Get more information